Blood pressure (BP) lowering might reduce the risk of cognitive impairment and dementia (CID), but more information is needed to design trials optimally.
Objective
To estimate trial sample sizes and durations for detecting BP-lowering effects on CID.
Methods
We estimated trial sample sizes and durations for finding an effect of a Systolic Blood PRessure INtervention Trial (SPRINT)-based BP-lowering strategy versus usual care on CID and global cognition using our MIchigan ChROnic Disease SIMulation Model (MICROSIM), which simulated adults with the US population's demographics and vascular risk factors and assumed BP-lowering's effect on CID and global cognition from our pooled cardiovascular cohort study.
Results
Over >139 million simulated trials across 78,000 parameters, the SPRINT-based BP-lowering strategy (versus usual care) resulted in a 2% CID relative risk reduction (RRR), much smaller than the CID RRR (15%) found in SPRINT Memory and Cognition IN Decreased Hypertension (MIND). Detecting a 2% CID RRR with >80% power would require 10-year trials with samples >50,000. Identifying the BP-lowering strategy's effect on mean global cognition would require trials of ≥10 years with >30,000 participants. However, trials of 5 years with 10,000 participants would have the power to detect the strategy's effect assuming a 15% CID RRR in SPRINT MIND.
Conclusions
In this microsimulation study, we found that trials would need to be large with long follow-ups to identify the causal effects of BP-lowering on CID and cognition. However, assuming the 15% CID RRR in SPRINT MIND, trials with more feasible sizes and durations could detect those effects.
GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health2022; 7: e105–e125.
2.
BaiWChenPCaiH, et al.Worldwide prevalence of mild cognitive impairment among community dwellers aged 50 years and older: a meta-analysis and systematic review of epidemiology studies. Age Ageing2022; 51: afac173.
3.
LivingstonGHuntleyJSommerladA, et al.Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet2020; 396: 413–446.
4.
WilliamsonJDPajewskiNMAuchusAP, et al.Effect of intensive vs. standard blood pressure control on probable dementia: a randomized clinical trial. JAMA2019; 321: 553–561.
5.
GhaziLShenJYingJ, et al.Identifying patients for intensive blood pressure treatment based on cognitive benefit: a secondary analysis of the SPRINT randomized clinical trial. JAMA Netw Open2023; 6: e2314443.
6.
BurkeJFCopelandLLSussmanJB, et al.Development and validation of the Michigan ChROnic Disease SIMulation model (MICROSIM). PLoS One2024; 19: e0300005.
7.
LevineDAGrossALBriceñoEM, et al.Association between blood pressure and later-life cognition among Black and White individuals. JAMA Neurol2020; 77: 810–819.
8.
BurkeJFSussmanJBYaffeK, et al.Effect of population-level blood pressure treatment strategies on cardiovascular and cognitive outcomes. Circ Cardiovasc Qual Outcomes2024; 17: e010288.
9.
LevineDASussmanJBHaywardRA, et al.The potential impact of optimal blood pressure treatment intensity to reduce disparities in dementia between Black and White individuals. J Alzheimers Dis2025; 103: 506–518.
10.
ChengAKesslerDMackinnonR, et al.Reporting guidelines for health care simulation research: extensions to the CONSORT and STROBE statements. Simul Healthc2016; 11: 238–248.
11.
MarmaAKBerryJDNingH, et al.Distribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults: findings from the National Health and Nutrition Examination Survey 2003 to 2006. Circ Cardiovasc Qual Outcomes2010; 3: 8–14.
12.
ArnoldBFHoganDRColford JrJM, et al.Simulation methods to estimate design power: an overview for applied research. BMC Med Res Methodol2011; 11: 94.
13.
BriceñoEMGrossALGiordaniBJ, et al.Pre-Statistical Considerations for Harmonization of Cognitive Instruments: harmonization of ARIC, CARDIA, CHS, FHS, MESA, and NOMAS. J Alzheimers Dis2021; 83: 1803–1813.
14.
The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol1989; 129: 687–702.
15.
FriedmanGDCutterGRDonahueRP, et al.CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol1988; 41: 1105–1116.
16.
FriedLPBorhaniNOEnrightP, et al.The Cardiovascular Health Study: design and rationale. Ann Epidemiol1991; 1: 263–276.
17.
FeinleibMKannelWBGarrisonRJ, et al.The Framingham Offspring Study: design and preliminary data. Prev Med1975; 4: 518–525.
18.
SaccoRLBoden-AlbalaBGanR, et al.Stroke incidence among White, Black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study. Am J Epidemiol1998; 147: 259–268.
19.
Wright JrJTWilliamsonJDWheltonPK, et al.A randomized trial of intensive versus standard blood-pressure control. N Engl J Med2015; 373: 2103–2016.
20.
DrawzPEAgarwalADwyerJP, et al.Concordance between blood pressure in the systolic blood pressure intervention trial and in routine clinical practice. JAMA Intern Med2020; 180: 1655–1663.
21.
TurnbullF. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet2003; 362: 1527–1535.
22.
BasuSSussmanJBHaywardRA. Detecting heterogeneous treatment effects to guide personalized blood pressure treatment: a modeling study of randomized clinical trials. Ann Intern Med2017; 166: 354–360.
23.
CareyRMCalhounDABakrisGL, et al.Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension2018; 72: e53–e90.
24.
WolinskyFDUnverzagtFWSmithDM, et al.The ACTIVE cognitive training trial and health-related quality of life: protection that lasts for 5 years. J Gerontol A Biol Sci Med Sci2006; 61: 1324–1329.
25.
UngerJMvan BelleGHeymanA. Cross-sectional versus longitudinal estimates of cognitive change in nondemented older people: a CERAD study. Consortium to Establish a Registry for Alzheimer’s Disease. J Am Geriatr Soc1999; 47: 559–563.
26.
RossettiHCMunro CullumCHynanLS, et al.The CERAD Neuropsychologic Battery Total Score and the progression of Alzheimer disease. Alzheimer Dis Assoc Disord2010; 24: 138–142.
27.
SeaboldSPerktoldJ. Statsmodels: econometric and statistical modeling with python. SciPy2010; 7: 92–96.
28.
Sprint Mind Investigators for the SPRINT Research GroupNasrallahIMPajewskiNM, et al.Association of intensive vs standard blood pressure control with cerebral white matter lesions. JAMA2019; 322: 524–534.
29.
HughesDJudgeCMurphyR, et al.Association of blood pressure lowering with incident dementia or cognitive impairment: a systematic review and meta-analysis. JAMA2020; 323: 1934–1944.
30.
PetersRXuYFitzgeraldO, et al.Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis. Eur Heart J2022; 43: 4980–4990.
GillettSRThackerELLetterAJ, et al.Correlates of incident cognitive impairment in the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study. Clin Neuropsychol2015; 29: 466–486.
33.
IvnikRJSmithGEPetersenRC, et al.Diagnostic accuracy of four approaches to interpreting neuropsychological test data. Neuropsychology2000; 14: 163–177.
34.
BreezePThomasCThokalaP, et al.The impact of including costs and outcomes of dementia in a health economic model to evaluate lifestyle interventions to prevent diabetes and cardiovascular disease. Med Decis Making2020; 40: 912–923.
